Loading…
Wanbury (WANBURY)₹200.71−0.14%Pharmaceuticals
Wanbury is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a P/E of 10.4 against a peer median of 38.2, and ROCE of 31.1% against a peer median of 13.1%, and latest-quarter sales growth of −4.1% against a peer median of 9.5%. By market cap it is #11 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jagsonpal Pharmaceuticals | 1,433 | 31.9 | 23.0 | 17.3 | 0.03 | 1.8 | 287 | 43 | 9.5 | 0.1 | vs WANBURY |
| Anlon Healthcare | 1,433 | 42.1 | 21.0 | 18.4 | 0.19 | 0.0 | 173 | 29 | 103.7 | 89.0 | vs WANBURY |
| Fermenta Biotech | 1,267 | 21.2 | 21.0 | 16.4 | 0.28 | 0.9 | 524 | 70 | −10.7 | −55.8 | vs WANBURY |
| Kopran | 1,252 | 50.0 | 7.0 | 4.9 | 0.29 | 1.2 | 683 | 26 | 13.9 | −10.0 | vs WANBURY |
| Bajaj Healthcare | 1,062 | 54.5 | 10.9 | 9.4 | 0.47 | 0.5 | 608 | 16 | 11.5 | 16.5 | vs WANBURY |
| Lincoln Pharmaceuticals | 1,043 | 10.8 | 16.0 | 12.0 | 0.01 | 0.3 | 672 | 88 | 17.3 | 0.0 | vs WANBURY |
| Sigachi Industries | 1,036 | 38.2 | 6.0 | 5.8 | 0.27 | 0.4 | 478 | −83 | −5.4 | — | vs WANBURY |
| Amanta Healthcare | 784 | 54.2 | 12.0 | 10.4 | 1.12 | 0.0 | 289 | 15 | 5.3 | −5.7 | vs WANBURY |
| Zim Laboratories | 735 | 180.1 | 5.0 | 1.6 | 0.43 | 0.0 | 374 | 6 | 31.4 | — | vs WANBURY |
| Kilitch Drugs (India) | 701 | 23.2 | 13.1 | 10.5 | 0.32 | 0.0 | 235 | 30 | 4.0 | −13.6 | vs WANBURY |
| Wanbury | 700 | 10.4 | 31.1 | 68.4 | 1.56 | 0.0 | 648 | 66 | −4.1 | 10.0 | — |
| Peer median | 1,043 | 38.2 | 13.1 | 10.5 | 0.29 | 0.3 | 478 | 29 | 9.5 | 0.0 |
Listed companies closest to Wanbury in Pharmaceuticals include Jagsonpal Pharmaceuticals, Anlon Healthcare, Fermenta Biotech, Kopran, Bajaj Healthcare, Lincoln Pharmaceuticals, Sigachi Industries, Amanta Healthcare.
Jagsonpal Pharmaceuticals, with a market cap of ₹1,433 Cr.
Wanbury trades at a P/E of 10.4; the median of its peer set is 38.2. A P/E above or below the median is a description, not a judgement on value.
Wanbury's return on capital employed is 31.1%, above the peer median of 13.1%.